1.
Bone Marrow Transplant
; 57(6): 1034-1037, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35430592
Assuntos
Leucemia Mieloide Aguda , Recidiva Local de Neoplasia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Compostos Bicíclicos Heterocíclicos com Pontes/uso terapêutico , Humanos , Leucemia Mieloide Aguda/tratamento farmacológico , Recidiva Local de Neoplasia/tratamento farmacológico , Piridonas , Pirimidinonas/farmacologia , Pirimidinonas/uso terapêutico , Sulfonamidas
2.
Case Rep Hematol
; 2020: 8894031, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33123389
RESUMO
Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refractory (R/R) disease course, which poses a major therapeutic challenge. New therapies, including BRAF V600E mutation targeting, may become a new treatment option for R/R MM. In combination with mitogen-activated protein kinase inhibitors (MEKi), BRAF inhibitors (BRAFi) could provide better tailored clinical management, although experience in this field is lacking. To this date, there is only one case describing R/R MM treatment with BRAFi vemurafenib and MEKi cobimetinib. This is the first case presenting a R/R MM patient treated with BRAFi dabrafenib and MEKi trametinib.